Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mutations in the RAS-RAF-MEK-ERK signaling pathway are common in various cancers and RASopathies.
• RAS oncogene activation impacts millions annually, with downstream RAF kinase alterations also contributing to cancer etiology.
• BRAF V600E mutations are prevalent oncogenic drivers, leading to targeted therapies.

Purpose of the Study:

• To review recent advancements in anti-RAF therapies.
• To critically evaluate the efficacy of novel approaches in overcoming therapeutic limitations.
• To explore the potential of these therapies in blocking the RAS pathway.

Main Methods:

• Literature review of recent research on anti-RAF therapies.
• Analysis of drug development targeting RAF alterations (Class I, II, and III).
• Evaluation of novel therapeutic strategies including paradox breakers, dimer-inhibitors, and immunotherapies.

Main Results:

• Current BRAFV600E-targeted drugs (Class I) can cause paradoxical pathway activation and resistance.
• Class II and III RAF alterations, involving dimerization, remain largely untreatable with existing therapies.
• Emerging therapies show promise in addressing resistance and targeting diverse RAF dimerization patterns.

Conclusions:

• Novel anti-RAF strategies are essential to overcome limitations of current treatments.
• Paradox breakers and dimer-inhibitors represent promising avenues for treating resistant and non-BRAFV600E RAF-driven malignancies.
• Further research into immunotherapies and other novel approaches may offer new treatment paradigms for RAS pathway-driven cancers.